Kelly Deck - 30 May 2024 Form 4 Insider Report for Inhibrx Biosciences, Inc. (INBX)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	INXB	Stock Option (right to buy)	Award	$0	+175,000		$0.000000	175,000	30 May 2024	Common Stock	175,000	$15.86	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.
F2	Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on May 30, 2025, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.